News & Events

We thank you for your trust and support in 2019 and we wish you all the best in the forthcoming year! Best wishes, Christian Schaub, CEO, on behalf of the Redbiotec Team.

2020 marks an exciting year ahead for Redbiotec as the team gears up for more milestones. New partnerships and investment in growth will be essential pillars towards achieving our vision.

Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD.  Dr. Calos is a Professor of Genetics at Stanford University.  A recent President of the American Society of Gene and Cell Therapy (ASGCT), Dr. Calos brings over four decades of research experience in genetics and genomic modification and has been focused on developing novel gene and cell therapies to improve the clinical condition of patients suffering from genetic disorders like muscular dystrophy.  Dr. Calos has also served on the Advisory Committee to the FDA with regard to cell, tissue and gene therapies. Dr. Calos is an Oxford graduate and received her PhD in Biochemistry & Molecular Biology from Harvard University.

As Redbiotec enters the field of gene therapy with engineered bacteria as means to improve in vivo delivery of therapeutics, we greatly appreciate the research experience and regulatory insights brought by Dr. Calos.

Redbiotec AG, a pioneer in living medicines, is pleased to announce the addition of Professor Christoph U. Schoen, MD, PhD to its Scientific Advisory Board. Dr. Schoen is a Professor of Medical Microbiology at the University of Würzburg, and the Head of the Laboratory for Diagnostic Microbiology, Institute for Hygiene and Microbiology. He is an expert in clinical microbiology, with 20 years of research experience and numerous scientific publications in the fields of patho-biotechnology, bacterial patho-genomics and diagnostic microbiology.  Dr. Schoen received his MD from Georg-August-University, and his PhD in Microbiology from Julius-Maximilians-University.

Christian Schaub, the CEO of Redbiotec, commented “We are thrilled that Professor Schoen has agreed to join our growing Scientific Advisory Board. He will be instrumental in helping our dedicated scientific team further the development of our proprietary platforms for living medicines.”

Redbiotec welcomes two new senior people: Dr. Jin Huh, a synthetic biology expert from the Massachusetts Institute of Technology (MIT) who shall provide scientific advisory to Redbiotec, and Dr. Yao Cheng joining Redbiotec as the Senior Business Development Manager. Redbiotec seeks to expand its growing scientific as well as business networks globally with these new appointments.

Redbiotec is pleased to announce the appointment of Dr. Antonio Marchini, head of Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the Luxembourg Institute of Health and German Cancer Research Center (DKFZ), as a member of our Scientific Advisory Board. Antonio is an expert in the field of oncolytic viruses aiming at developing innovative anticancer agents. Redbiotec looks forward to this collaboration.